MedPath

Celonova Biosciences, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:1
Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (75.0%)
Phase 1
1 (25.0%)

Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry

Completed
Conditions
Stable Angina
NSTEMI - Non-ST Segment Elevation MI
Unstable Angina
STEMI
ACS - Acute Coronary Syndrome
Myocardial Infarction
First Posted Date
2017-04-06
Last Posted Date
2018-08-07
Lead Sponsor
CeloNova BioSciences, Inc.
Target Recruit Count
1027
Registration Number
NCT03103620
Locations
🇫🇷

Clinique Axium, Aix, France

🇫🇷

GCS Cardio, Annecy, France

🇫🇷

SCM Angioscan, Antony, France

and more 12 locations

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Not Applicable
Conditions
Angina, Stable
Anticoagulants
Angina, Unstable
First Posted Date
2015-11-03
Last Posted Date
2020-10-26
Lead Sponsor
CeloNova BioSciences, Inc.
Target Recruit Count
996
Registration Number
NCT02594501
Locations
🇺🇸

Christiana Care Health Services, Newark, Delaware, United States

🇺🇸

University of Florida, Jacksonville, Florida, United States

🇺🇸

Memorial Hospital Jacksonville, Jacksonville, Florida, United States

and more 45 locations

COBRA SHIELD OCT Study

Not Applicable
Terminated
Conditions
Stable Angina
Interventions
Device: COBRA PzF
Device: Resolute Integrity DES
First Posted Date
2014-08-25
Last Posted Date
2020-10-06
Lead Sponsor
CeloNova BioSciences, Inc.
Target Recruit Count
8
Registration Number
NCT02224235
Locations
🇫🇮

Satakunta Central Hospital, Pori, Finland

🇫🇮

Heart Center, Turku University Hospital, Turku, Finland

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

Not Applicable
Completed
Conditions
Coronary Artery Disease
First Posted Date
2013-08-20
Last Posted Date
2021-12-22
Lead Sponsor
CeloNova BioSciences, Inc.
Target Recruit Count
296
Registration Number
NCT01925794
Locations
🇺🇸

Bakersfield Memorial Hospital, Bakersfield, California, United States

🇺🇸

Mt Sinai Medical Center, Miami Beach, Florida, United States

🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

and more 32 locations

REVEAL Study: Vessel Healing After Angioplasty

Completed
Conditions
Coronary Artery Disease
First Posted Date
2008-11-27
Last Posted Date
2014-01-16
Lead Sponsor
CeloNova BioSciences, Inc.
Target Recruit Count
34
Registration Number
NCT00799344
Locations
🇮🇹

Ferrarotto Hospital, Catania, Sicily, Italy

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.